NBIX vs SUPN
NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | NBIX | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $174.15 | $47.19 | |
| Market cap as of 2026-07-26 | $17.7B | $2.7B | |
| P/E as of 2026-07-26 | 26.43 | n/a | |
| PEG as of 2026-07-26 | 0.22 | n/a | |
| Net margin as of 2026-07-26 | +21.6% | -3.7% | NBIX higher |
| Gross margin as of 2026-07-26 | +98.2% | +89.7% | NBIX higher |
| Operating margin as of 2026-07-26 | +25.4% | -7.8% | NBIX higher |
| ROE as of 2026-07-26 | +21.6% | -2.7% | NBIX higher |
| ROA as of 2026-07-26 | +15.1% | -2.0% | NBIX higher |
| Debt / equity as of 2026-07-26 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-26 | +28.6% | +16.3% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +24.3% | +2.5% | NBIX higher |
| Beta as of 2026-07-26 | 0.39 | 0.57 | |
| 1-year return as of 2026-07-23 close | +33.5% | +40.6% | SUPN higher |
Fundamentals: Finnhub, as of 2026-07-26. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.